Correspondence 0001683168-23-006761 from PharmaCyte Biotech, Inc. (PMCB)
PharmaCyte Biotech, Inc.
Date: Sept. 27, 2023 · CIK: 0001157075 · Accession: 0001683168-23-006761
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272569
Letter
PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, NV 89169
September 27, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Doris Stacey Gama and Joe McCann
Re: PharmaCyte Biotech, Inc.
Registration Statement on Form S-3
Filed September 12, 2023
File No. 333-272569 (the “Registration Statement”)
Acceleration Request
Ladies and Gentlemen:
In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, PharmaCyte Biotech, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, September 29, 2023, at 4:01 p.m., Eastern Time, or as soon as thereafter practicable.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request.
Very truly yours,
PHARMACYTE BIOTECH, INC.
Show Raw Text
CORRESP 1 filename1.htm PharmaCyte Biotech, Inc. 3960 Howard Hughes Parkway, Suite 500 Las Vegas, NV 89169 September 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama and Joe McCann Re: PharmaCyte Biotech, Inc. Registration Statement on Form S-3 Filed September 12, 2023 File No. 333-272569 (the “Registration Statement”) Acceleration Request Ladies and Gentlemen: In accordance with Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, PharmaCyte Biotech, Inc. (the “Registrant”) hereby respectfully requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement to Friday, September 29, 2023, at 4:01 p.m., Eastern Time, or as soon as thereafter practicable. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please contact Daniel A. Bagliebter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel to the Registrant, at (212) 692-6856 with any questions regarding this request. Very truly yours, PHARMACYTE BIOTECH, INC. /s/ Joshua N. Silverman Joshua N. Silverman Interim Chief Executive Officer and Interim President cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Kenneth R. Koch, Esq. Daniel A. Bagliebter, Esq.